Has Lilian Chen, MD received payments from drug or device companies?

Yes. Drug and device makers reported $47,725 in general payments to Lilian Chen, MD across 143 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Lilian Chen, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Lilian Chen, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Lilian Chen, MD

Colon & Rectal Surgery · Boston, MANPI 1780813055

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (32.3%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. Applied Medical Resources Corporation accounts for 74.7% of it on its own, with 24 other manufacturers making up the rest. 2025 is the largest year on record at $29,137, more than ten times the $666 reported in 2019.

$47,725in general payments, 2019–2025

Across 143 payments — averaging $333.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Applied Medical Resources Corporation$36K
Dilon Technologies, Inc.$3K
Deroyal Industries, Inc.$2K
Biom'up France SAS$2K
Intuitive Surgical$2K
Aroa Biosurgery Incorporated$2K
plus $2K from 19 others

What the payments were for

Consulting fees$11,83825%
Speaking & faculty fees$15,40032%
Travel & lodging$10,19621%
Food & beverage$8,62218%
Education$1,6703%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Applied Medical Resources Corporation	38	$35,660
Dilon Technologies, Inc.	25	$3,082
Deroyal Industries, Inc.	2	$2,492
Biom'up France SAS	13	$1,755
Intuitive Surgical	2	$1,670
Aroa Biosurgery Incorporated	23	$1,537
Integra Lifesciences Corporation	8	$320
W. L. Gore & Associates, Inc.	2	$211
Smith+Nephew	10	$177
AbbVie	1	$136
Medical Device Business Services, Inc.	1	$103
Takeda Pharmaceuticals U.S.A., Inc.	2	$91
Johnson & Johnson	2	$75
Innovation Technologies Inc	1	$71
Axonics, Inc.	2	$63
Acera Surgical, Inc.	2	$38
Kerecis Limited	1	$37
Convatec Inc.	1	$35
Merck	1	$33
Boston Scientific	1	$28
Medtronic	1	$26
Polynovo North America LLC	1	$25
TELA Bio, Inc.	1	$22
Polarityte, Inc.	1	$20
Conmed Corporation	1	$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Gelport Laparoscopic System$19,581
HemoBlast Bellows$4,265
Prospera PRO Negative Pressure Wound Therapy Units$2,400
DAVINCI XI$1,500
GELPORT$400
INTEGRA$312
Da Vinci Surgical System$170
GORE ENFORM Preperitoneal Biomaterial$160
NAVIGATOR BIONAVIGATION SYSTEM$145
STRATTICE$136
INTEGRA DERMAL REGENERATION TEMPLATE$104
PRIMATRIX$104
Enseal$103

How this compares

$47,725 in reported general payments places this provider in the 85th percentile of 49 colon & rectal surgery providers in Massachusetts.

See all colon & rectal surgery providers in Massachusetts →

Medicare billing

Part B allowed, 2024

$62,994

Medicare patients

109

Services billed

264

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Colestipol Hcl	26	$1,580
LoperamideLoperamide Hcl	12	$344
Diclofenac Sodium	11	$335
Ammonium Lactate	12	$224
Hydrocortisone	11	$126
Amitriptyline Hcl	14	$44

Paid to pharmacies, not to this prescriber.

Other colon & rectal surgery in Boston

Patricia SyllaBoston$139K
Jennifer DavidsBoston$36K
Deborah NagleBoston$33K
Olga BeresnevaBoston$30K
Amanda CimsitBoston$25K
Robert GoldstoneBoston$22K
Melissa MurphyBoston$13K
Hiroko KunitakeBoston$11K
James YooBoston$8K
Jennifer IraniBoston$7K

See the full list for Massachusetts →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →